Project Grant R01HL182418
Award Date 9/1/26
Completion Date 5/31/30
Dollars Obligated $367K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Baltimore, MD 21205, USA
Similar Awards
- The National Heart, Lung, and Blood Institute awarded Emory University $783,830 under the Cardiovascular Diseases Research program (CFDA 93.837) on July 15, 2026, to conduct a prospective cohort study examining vascular endothelial function, ovarian hormones, inflammatory response, and hypertension incidence in women of reproductive age with and without HIV. The project, titled HIV and Endothelial Function in Women of Reproductive Age (HEART), will enroll 400 participants from Atlanta and...
- The National Heart, Lung, and Blood Institute awarded Northern California Institute For Research And Education, Inc. (NCIRE) $3.002 million on August 7, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct a prospective longitudinal study of cardiac fibro-inflammation progression in women with HIV. The research repeats cardiac magnetic resonance imaging in returning participants approximately eight years after their initial scans, drawing from the MACS-WIHS...
- The National Heart Lung and Blood Institute awarded New York University $510,538 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct a hybrid effectiveness-implementation study integrating the HEARTS package—a World Health Organization–recommended strategy comprising healthy lifestyle counseling, evidence-based treatment protocols, access to medicines, risk-based care, task-sharing, and systems monitoring—into primary healthcare centers in Nigeria...
- Federal Project Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded the University of Alabama at Birmingham $223,438 on September 4, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct a clinical research study examining hypertension incidence in people with HIV initiating antiretroviral therapy (ART). The project, scheduled for completion by August 31, 2027, will assess blood pressure outcomes in ART-naïve individuals starting either...
- The National Heart, Lung, and Blood Institute awarded $1.555 million to the University of Maryland, Baltimore on August 5, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to model and treat chronic HIV-induced lung infections. The research investigates immune mechanisms underlying increased susceptibility to respiratory infections in people living with HIV. The project focuses on how chronic HIV infection impairs dendritic cell differentiation and function, hypothesizing...
- The National Heart, Lung, and Blood Institute awarded the University of California, Los Angeles $1,282,827 on July 10, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct a multicenter randomized placebo-controlled trial evaluating glucagon-like peptide-1 receptor agonist therapy on inflammation and atherosclerosis in persons living with HIV. The study will enroll 125 treatment-suppressed participants aged 40 and older with known cardiovascular disease or at least...
- The National Heart, Lung, and Blood Institute awarded Icahn School of Medicine at Mount Sinai $462,000 on August 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct comparative analysis of thrombogenic risk across menopausal stages in women with HIV. The research examines sex-based differences in cardiovascular disease risk among women with HIV, focusing on how immune activation, platelet reactivity, and age-related changes in sex hormones interact to elevate...
- The National Heart, Lung, and Blood Institute of the Department of Health and Human Services awarded Duke University $798,698 on September 10, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate cardiac function and proteomic biomarkers in youth with perinatal HIV infection. The award funds comprehensive phenotyping combining cardiac imaging, physical function assessment, autonomic dysfunction measurement, and molecular profiling to identify imaging and...
- The National Institute of Child Health and Human Development awarded The Johns Hopkins University $415,839 on September 15, 2025, under the Child Health and Human Development Extramural Research program (CFDA 93.865) to conduct a longitudinal study of anti-müllerian hormone and fecundability in women living with HIV in Africa. The project examines the association between lifelong antiretroviral treatment and reproductive hormone markers, specifically anti-müllerian hormone as a measure of...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a $2.98 million Project Grant (CFDA 93.837 – Cardiovascular Diseases Research) to the University of California, San Francisco to conduct a four-year research study examining the impact of asymptomatic cytomegalovirus (CMV) infection on cardiovascular event risk in people with HIV (PWH). The primary deliverable is a large-scale Mendelian randomization study that will assess whether CMV-associated plasma proteomic signatures and...